In line with the oncogenic functions of PLUM-EZH2, s-ASO-g11 and s-ASO-g12 treatment reduced the proliferation of MM cells, whilst increasing the percentage of apoptotic cells (by ~10%) (Fig. 5h, i and Supplementary Fig. 6e, f). This evidence concerns the gene EZH2 and Miyoshi myopathy.